Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: Katie Kommando who wrote (19769)	1/12/2000 12:26:00 AM
From: johnsto1	Respond to of 150070

ARIA...is there more to the story The ‘billion dollar' quote by: Aurileano 1/11/00 11:41 pm Msg: 3615 of 3618 From the abstract of patent #6,011,018 (which, from my, scannning covers the entire ARGENT platform): ‘…the dimerizers (i.e. the molecules driving ARGENT) have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression.' If you want a billion dollar drug, I would guess a ‘universal drug' certainly wouldn't hurt. Nor would it hurt much if self same drug replaced antisense therapy or other approaches requiring iv injections. -------------------------------------------- I've followed Ariad's science for 2+ years and I'm quite familiar with it. The events of the last ~2 weeks have not involved any new scientific data (although I'm not yet aware of the data presented at Keystone). The most recent publication by the company, the ‘clustering' paper published 6 weeks in PNAS, was consistent with all the previous work from the company: absolutely top notch science with a distinctly creative flair. The major changes that have occurred have happened outside the scientific realm: 1. the company has received $40 million from HMR from the sale of its 50% stake in the genomics facility and 2. today's news regarding the patents. While my background is in sceince (and that is what brought me to Ariad – it's the only biotech stock I've ever owned), the recent events put the company on a substantially firmer foundation than even 4 weeks ago. Not only does the company have cash and a much narrower focus (good) with a very strong platform (ARGENT), the ‘formalizing' of this platform with the patent announcement today virtually assures Ariad (IMO) a steady and rapidly growing income from the licensing revenue (and their own ARGENT based applications). Today's response by the market, as reflected especially by the volume, was a belated recognition that ARGENT may indeed be an incredibly valueable reagent; a reagent whose potential uses really are almost unimaginable and a reagent that many other companies could apply to numerous CURRENT approaches. With the patent now in effect, Ariad has locked in place the foundation for a potentially tremendous revenue stream. I've been making statements to this effect, on this thread, for over two years. A couple of the other oldtimers have as well. Following the events of the past 2 weeks, it would seem there are now a couple more folks who agree with our assessment of ARGENT. Posted as a reply to: Msg 3605 by Pirkkal Go to Msg #: < Previous \| Next > [ First \| Last \| Msg List ]

To: Katie Kommando who wrote (19769)	1/12/2000 12:53:00 AM
From: Jim Bishop	Respond to of 150070

Perfect Katie, just what I was looking for. I'll pass it on to MJXC as a sort of precedent news, LOL in fact I just emailed a copy of it to the in house IR. KWINE I've been watching. One of those guys I was talking to at that Florida IR place, forget the name, told me he expected KWINE to lose the E, I think Monday, take it with a grain, but from the trading, I'd say market agrees.